Kura Oncology Inc
KURA
Get informed when a big investor buys or sells
+ FollowMarket Cap$941.01M
Close$
$13.04
43.6% upside
Current Fair Value
43.6% upsideUndervalued by 43.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $941.01 Million |
|---|---|
| Enterprise Value | $950.70 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.18 |
| Beta | 0.38 |
| Outstanding Shares | 88,855,000 |
Return
| Return on Equity | -612.78% |
|---|---|
| Return on Assets | -50.49% |
| Return on Invested Capital | -66.66% |
Valuation & Multiples
| P/E Ratio | -3.15 |
|---|---|
| PEG | -94.32 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 12.31 |
| Enterprise Value to EBIT | -3.04 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 1.65 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.88
Average shareholder expectationRevenue Estimate
$20.16 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.81
Average shareholder expectationRevenue Estimate
$23.81 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 18.46% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 98.61% |
|---|---|
| Total Invested | $51,912▼ 99.99% |
| Investors Holding | 5▼ 222.00% |
ESG Score
No data
About Kura Oncology Inc
CEO: Troy Wilson